ROCKVILLE, Md., Aug. 12, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) (“the Company”), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced today that, on August 10, 2009, it entered into securities purchase agreements with investors to raise gross proceeds of approximately $1,050,000, before placement agent’s fees and other offering expenses, in a registered direct offering.
